CRWV closed Tuesday at $99.81 — down 7.4% on the week and more than 14% over the past month — and the first outright downgrade since its Q1 report has landed just as the stock tests that psychologically important level.
DA Davidson's Gil Luria cut CRWV to Neutral from Buy on Monday, slashing his target from $175 to $100. That move stands out not just for its timing — the stock is now essentially trading at his revised target — but for its contrast with the rest of the Street. Most analysts who updated after the May 7 earnings print lifted their numbers: Cantor Fitzgerald raised to $167, Citigroup to $158, Wells Fargo to $155, and Jefferies to $160. The consensus remains Buy, with a mean target of $138.90, implying nearly 40% upside from current levels. But that gap between target and price has been widening for weeks, and the Davidson downgrade is a signal that at least one firm is reassessing whether the re-rating thesis is stalling. JPMorgan and Barclays sit on the cautious side too — both Neutral-rated, with targets of $105 and $120 respectively — meaning the sceptics now have more company.
The short positioning adds texture to that divide. Short interest is running at 15.6% of the free float — a genuinely elevated level — but it has barely moved this week, down less than 1% from where it was seven days ago. More telling is the direction over the past month: SI has fallen roughly 10% from its April peak, when it briefly reached above 66 million shares in mid-April. That earlier build now looks like it reflected real concern ahead of earnings; since the print, shorts have been covering rather than pressing. Borrow conditions reinforce this read. Cost to borrow is just 0.43% — effectively negligible — and availability is wide at around 800% of short interest, meaning there are roughly eight shares available to borrow for every one currently lent out. The lending market is not tight. There is no squeeze setup here.
Options positioning tells a similarly neutral story. The put/call ratio is 0.83, sitting fractionally below its 20-day average of 0.84, with a z-score near zero. That's essentially no signal — options traders are neither hedging aggressively nor piling into calls. The 52-week range runs from 0.56 to 2.04, so the current reading is firmly in the middle. After the sharp post-earnings drop — CRWV fell 17.3% the day after its May 7 results, and was still down 17.2% five days later — options positioning might reasonably be expected to skew more defensive. That it hasn't shifted much suggests the market is in a wait-and-see mode rather than actively repositioning around the next catalyst.
That catalyst arrives on June 8, when CoreWeave reports again. The earnings history here is short but pointed: the one print with meaningful data produced a 17% single-day decline. The bull case rests on durable AI infrastructure demand, expanding contracts with hyperscalers, and what analysts describe as strong forward EBITDA growth. The bear case centres on customer concentration — a handful of large clients dominate revenue — and the capital intensity required to keep pace with demand. Founder and Chief Strategy Officer Brian Venturo sold roughly $3.5 million of stock across multiple transactions on May 13, and the Chief Accounting Officer sold a further $4.8 million the following day. Neither sale is enormous in the context of the company's float, and the 90-day net insider figure is positive at $39.2 million, suggesting earlier purchases have offset recent distributions. Still, the timing — selling into weakness, days after the earnings slide — is worth noting. Close peer APLD dropped 16.6% on the week, and BBAI fell 8.4%, so the pressure on CRWV is not isolated to the name.
The June 8 print will test whether the Street's 19-11 buy-to-hold split holds at $100, or whether the DA Davidson move marks the beginning of a broader reassessment.
See the live data behind this article on ORTEX.
Open CRWV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
